Sanofi
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 6, 2025), Sanofi reported 9 stock positions worth $165.9 million. Its top holding was Meiragtx (MGTX) at 49.8% of the portfolio, followed by Novavax (NVAX, 26.6%) and Inhibrx Biosciences (INBX, 9.8%). Its holdings were unchanged from Q4 2024.
- Most Recent 13F
- Q2 2026
- Location
- Paris, I0
- CIK
- 0001121404
- Portfolio Value
- $165.9M (Q1 2025)
- SEC Filing
- 0000950123-25-004066 ↗ filed May 6, 2025
Holdings Value
Holdings 9 stocks · $165.9M
| MGTX Meiragtx Holdings PLC | 49.84% | 12,197,737 | $82.7M | No change |
| NVAX Novavax Inc. | 26.58% | 6,880,481 | $44.1M | No change |
| INBX Inhibrx Biosciences Inc. | 9.76% | 1,157,926 | $16.2M | No change |
| ANAB Anaptysbio Inc. | 9.21% | 821,917 | $15.3M | No change |
| ELDN Eledon Pharmaceuticals Inc. | 1.66% | 814,980 | $2.8M | No change |
| LVTX Lava Therapeutics NV | 1.47% | 1,919,455 | $2.4M | No change |
| IGMS Igm Biosciences Inc. | 1.00% | 1,438,975 | $1.7M | No change |
| INZY Inozyme Pharma Inc. | 0.24% | 443,255 | $403K | No change |
| QTTB Q32 Bio Inc. | 0.24% | 244,083 | $403K | No change |
Portfolio Sells Q4 2024 → Q1 2025
| None this quarter. | |||
Portfolio Buys Q4 2024 → Q1 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $534.0M | MGTX, INBX, NVAX, ANAB, ODTX |
| Q1 2026 | 9 | $336.0M | MGTX, INBX, NVAX, ANAB, AGMB |
| Q4 2025 | 8 | $310.4M | MGTX, INBX, NVAX, ANAB, IMRX |
| Q3 2025 | 9 | $260.4M | MGTX, NVAX, INBX, ANAB, IMRX |
| Q2 2025 | 10 | $175.7M | MGTX, NVAX, ANAB, INBX, OMDA |
| Q1 2025 | 9 | $165.9M | MGTX, NVAX, INBX, ANAB, ELDN |
| Q4 2024 | 9 | $174.4M | MGTX, NVAX, INBX, ANAB, IGMS |